Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2008-01-01
2008-01-01
Canella, Karen A. (Department: 1643)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023400, C536S023530
Reexamination Certificate
active
07314753
ABSTRACT:
The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules inE. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
REFERENCES:
patent: 5648237 (1997-07-01), Carter et al.
patent: 0590530 (1992-02-01), None
patent: 0 501 215 (1992-09-01), None
patent: 0590530 (1993-09-01), None
patent: 0 623 352 (1994-04-01), None
patent: WO 93/22334 (1993-11-01), None
Wang et al (Cancer Research, 1992, vol. 52, pp. 4484-4491.
Bosslet et al (Cancer Research, 1994, vol. 54, pp. 2151-2159).
Gussow et al.; “Humanization of Monoclonal Antibodies”, Methods in Enzymology; vol. 203; (1991); pp. 99-121.
Bosslet et al.; “Molecule and Funcational Characterization of a Fusion Protein Suited for Tumor Specific Prodrug Activation”; Br. J. Cancer; vol. 65; (1992); pp. 234-238.
Derman et al.; “Mutations that Allow Disulfide Bond Formation in the Cytoplasm ofEscherichia coli”; Science; vol. 262; (1993); pp. 1744-1747.
Jefferson et al.; “B-Glucuronidase fromEscherichia colias a Gene-Fusion Marker”; Proc. Natl. Acad. Sci.; vol. 83; (1986); pp. 8447-8451.
Ayala et al.; “Bacertial Single-Chain Antibody Fragments, Specific for Carcinoembryonic Antigen”; BioTechniques; vol. 13, No. 5; (1992); pp. 790-799.
Goshorn et al.; “Genetic Construction, Expression, and Characterization of a Single Chain Anti-Carcinoma Antibody Fused to B-Lactamase”; Cancer Res.; vol. 53; (1993); pp. 2123-2127.
Amann et al.; “Tightly Regulated tac Prometer Vectors Useful for the Expression of Unfused and Fused Proteins inEscherichia coli”; Gene; vol. 69; (1983); pp. 301-315.
Bashawe; “Towards Generating Cytotoxic Agents at Cancer Sites”; Br. Jr. Cancer; vol. 60; (1989); pp. 275-281.
Pluckthun et al.; “Expression of Functional Antibody Fv and Fb Fragements inEscherichia coli”; Methods in Enzymology; vol. 178; (1989); pp. 497-515.
Rodrigues et al.; “Development of a Humanized Disulfide-stabilized Anti-p 185 Fv-B-lactamase Fusion Protein for Activation of a Cephalosporin Doxorubicin Prodrug”, Cancer Research; Jan. 1, 1995, vol. 55; pp. 63-70, Baltimore, Maryland.
Gillies et al; Human Antibodies Hybridomas; vol. 1, No. 1; pp. 47-54, 1990.
Axelsson; Acta Chemica Scandanavica Series B; vol. 39, No. 1; pp. 69-77, 1985.
Paulus et al.; Behring Inst. Mitt.; No. 78; pp. 118-132, 1985.
Burgess et al.; Journal of Cell Biology; vol. 111; pp. 2129-2138, 1990.
Lasar et al; Molecular and Cellular Biology; vol. 8, No. 3; pp. 1247-1252, 1988.
Schwartz et al.; Proc. Natl. Acad. Sci. USA; vol. 84; pp. 6408-6411, 1987.
Lin et al.; Biochemistry USA; vol. 14; pp. 1559-1563, 1975.
Haisma et al., “A monoclonal antibody- B-glucuronidase conjugate as a activator of the prodrug epirubicin-glucuronide for specific treatment of cancer”, Br. J. Cancer, pp. 474-478, Sep. 1992, vol. 66, No. 3.
He et al., “Functional expression of a single-chain anti-progesterone antibody fragment in the cytoplasm of a mutantEscherichia coli”, Nucleic Acids Research, pp. 4009-4010, 1995, Vo. 23, No. 19, Oxford University Press.
Qui, J., Swartz, J., Georgiou, G., (1998), “Expression of Active Human Tissue-Type Plasminogen Activator inEscherichia coli”, Applied and Environmental Microbiology, Dec. 1998, 64:4891-4896, American Society for Microbiology, Washington, D.C., USA.
Wöm, A., and Plückthun, A., “An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly”, FEBS Letters 427 (1998) 357-361, Federation of European Biochemical Societies, Amsterdam, Holland.
Wöm, A., Auf der Maur, A., Escher, D., Honegger, A., Barberis, A., and Plückthun, A., “Correlation between in Vitro Stability and in Vivo Performance of Anti-CGN4 Intrabodies as Cytoplasmic Inhibitors”, (2000) The Journal of Biological Chemistry vol. 275, No. 4, Issue of Jan. 28, 2795-2803, American Society for Biochemistry and Molecular Biology, Baltimore, Maryland, USA.
Proba et al., “Funcational antibody single-chain fragments from the cytoplasm ofEscherichia coli: influence of thioredoxin reductase”, Gene, vol. 159, No. 2, pp. 203-207, 1995.
Emery et al., “Strategies for Humanizing Antibodies” in Antibody Engineering, 2nd edition, Carol Borrebaeck, Ed., Oxford University Press, pp. 159-183, 1995.
Buchner et al., “A method for increasing the yield of properly folded recombinant fusion proteins”, Anal Biochem, vol. 205, pp. 263-270, 1992.
Hochman et al., Biochemistry, 1976, vol. 15, pp. 2706-2710.
Goto et al., Journal of Molecular Biology, 1982, vol. 156, pp. 911-926.
Skerra et al., 1988, vol. 240, 1038-1043.
Bosslet Klaus
Czech Joerg
Opper Martin
Canella Karen A.
Krupen Karen I.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Cytoplasmic expression of antibodies, antibody fragments and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytoplasmic expression of antibodies, antibody fragments and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytoplasmic expression of antibodies, antibody fragments and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2785879